Is Cerenome going out of business?

CERENOME, INC. (PSTV) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

CERENOME, INC. (PSTV) scores 17 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: FCF margin: -399.81%

Five questions, kept separate

Survival - Critical

4-6 mo of estimated runway from 2026-06-30, based on $8.6M of cash and short-term investments against $20.8M of annual burn. A disclosed filing event caps this reading; Event Risk carries the detail.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Evidence incomplete

A positive current market capitalization is unavailable, so price-to-fundamentals evidence cannot be computed.

Event risk - Critical event risk

Going-Concern Warning is the decisive filing event; one adverse event family is active. It appears across 2 scanned filings. Favorable events are shown separately and do not offset adverse risk.

What the rules read

• FCF margin: -399.81%
• Debt / Equity: -1.56x (Net Cash)
• Filing event risk: Going-Concern Warning (-8 pts)
• Cash Runway (years): 0.41y
• Revenue growth YoY: -70.43% (YoY)
• Return on Assets: -159.56%
• Cash Burn Deceleration: -420.63% QoQ improvement (Worsening)
• Price / Earnings: Unprofitable (see Valuation)
• Effective Tax Rate: 0.00% (loss-making)

Read from filings through 2026-08-14.

Price as of 2026-01-05.